MTOR and breast carcinoma: Data generated from this study suggests that inhibitors of the PI3K/AKT/mTOR pathway may be a viable strategy for many breast cancer patients, considering 59% of IDCs had measurable levels of PIK3CA mutation, and 26% of IDCs had levels of PIK3CA mutation ≥ 1 × 10−3.